Clinical research progress of BTK inhibitors in the treatment of mantle cell lymphoma
10.3969/j.issn.1006-5725.2024.17.002
- VernacularTitle:BTK抑制剂治疗套细胞淋巴瘤的临床研究进展
- Author:
Sishi XU
1
;
Pei-Pei YE
Author Information
1. 宁波大学医学部(浙江宁波 315211)
- Keywords:
BTK inhibitor;
relapsed;
refractory;
mantle cell lymphoma;
targeted therapy
- From:
The Journal of Practical Medicine
2024;40(17):2363-2368
- CountryChina
- Language:Chinese
-
Abstract:
Mantle cell lymphoma(MCL)is a rare B-cell non-Hodgkin's lymphoma characterized by clini-cal and pathological features encompassing both indolent and aggressive subtypes.Significant progress has been made in the past decade regarding the development of novel therapeutic options for MCL.Particularly,Bruton's tyrosine kinase inhibitor(BTKi)has exhibited remarkable efficacy in treating patients with MCL by specifically targeting the BTK protein,thereby inhibiting B-cell proliferation and inducing potent anti-tumor effects.Currently,global approval has been granted to five BTK inhibitors for MCL treatment,including the first-generation Ibrutinib,second-generation Acalabrutinib,Zanubrutinib,Orelabrutinib,as well as the non-covalent BTKi Pirtobrutinib.This review provides a comprehensive summary of findings from clinical trials investigating the use of BTKi in MCL treatment and offers valuable insights for clinical practice.
